The group has over 20 years of experience in clinical and translational research on Alzheimer’s disease. The main scientific interest is the use of neuroimaging techniques and other biomarkers in persons with or at risk for cognitive impairment. Acquisitions and innovations in fundamental neurosciences, ICT, and technology are uptaken and translated for use into a clinical setting for better pathophysiological understanding, diagnosis, prognosis, disease tracking, drug therapy, and rehabilitation. Specific topics of investigation are: the clinical use of imaging and fluid biomarkers; in vivo neurobiology of Alzheimer’s disease; the clinical use of innovative PET ligands; harmonisation of imaging markers for clinical use; development of innovative image analysis environments based on advanced ICT technology.
Cortical Superficial Siderosis: A Descriptive Analysis in a Memory Clinic Population.
A metabolite-based machine learning approach to diagnose Alzheimer-type dementia in blood: Results from the European Medical Information Framework for Alzheimer disease biomarker discovery cohort.
Metabolic correlates of dopaminergic loss in dementia with lewy bodies.
The A/T/N model applied through imaging biomarkers in a memory clinic.
Département de psychiatrie